Side-by-Side: How Annex 1 2022 Transforms Compliance from 2008
Annex 1 2008 is the basis for the 2022 version. This paper provides an easy-to-understand side by side comparison of the Annex 1 2008 v. 2022 versions, broken down by section.
In the dynamic world of aseptic pharmaceutical manufacturing, regulatory frameworks are evolving—and staying compliant is more important than ever. The 2022 revision of EU GMP Annex 1, now fully in effect as of August 2023, redefines contamination control for sterile drug production in the EU and imports.
This comprehensive rewrite of the 2008 version, nearly quadrupling in length, introduces a holistic approach to contamination control. The revised Annex 1 emphasizes strategic control over mere measurement, aligning more closely with global standards from WHO, PIC/S, and the FDA.
Key updates include:
-
Contamination Control Strategy (CCS): A central, facility-wide framework for managing contamination risks, shifting from reactive to proactive control.
-
Quality Risk Management (QRM): Embedded as a core principle for defining processes, operations, and limits—integrating seamlessly with CCS to balance product protection against risk.
-
Structural Reorganization: Clear separation of Certification (Section 4) and Monitoring (Section 9) for expanded guidance on facility design/qualification and ongoing routine monitoring.
While the core principles of environmental monitoring remain intact, enhanced descriptions and clarified guidance make risk assessments more actionable and easier to implement. For quality assurance teams in 2025, Annex 1 isn’t just about compliance—it’s a roadmap for driving continuous improvement and maintaining product integrity in an increasingly complex regulatory landscape.
Learn more… Complete the form to download the full paper.
